-
9 pharmaceutical and biological companies issued repurchase plans, most of which exceeded 100 million yuan
Time of Update: 2022-05-02
Tigermed announced on the evening of February 14 that the company plans to use its own funds or self-raised funds to repurchase some of the company's A shares through centralized bidding transactions, with a repurchase amount of not less than 250 million yuan and not more than 50 million yuan.
-
The pharmaceutical manufacturing industry will see strong profit growth in 2021, with a year-on-year increase of nearly 80%
Time of Update: 2022-05-02
Among them, the pharmaceutical manufacturing industry will see strong profit growth in 2021, with a year-on-year increase of nearly 80% .
-
Can Shimai Pharmaceutical get hundreds of millions of financing again to stir up the tens of billions of anti-dumping rivers and lakes?
Time of Update: 2022-05-02
According to reports, the company's world's first EGFR/CD3 bispecific antibody has recently been approved for clinical use, which is expected to become a major breakthrough in the treatment of CD3 dual antibodies from hematological tumors to solid tumors .
-
Shanghai Suspends Xinfeng Pharmaceutical's Procurement Qualification for Luotongding Sulfate Injection for 1 Year
Time of Update: 2022-05-02
On February 24, 2022, the Shanghai Pharmaceutical Centralized Tendering and Procurement Administration issued a notice on the suspension of the procurement qualification of Luotongdine Sulfate Injection produced by Guangdong Xinfeng Pharmaceutical Co.
51), the procurement qualification of Luotongding Sulfate Injection produced by Guangdong Xinfeng Pharmaceutical Co.
-
Nanxin Pharmaceutical's 2021 performance: total revenue of 687 million yuan, a year-on-year decrease of 36.81%
Time of Update: 2022-05-02
02% over the same period of the previous year; The net profit of shareholders of the listed company was -176 million yuan, a decrease of 232.
-
This anticoagulant drug market with sales of over 100 million has added another entrant!
Time of Update: 2022-05-02
The industry pointed out that for the generic drug of apixaban, a blockbuster product, the country is already in a situation of competition for hegemony, and it is uncertain which pharmaceutical company can win in the domestic anticoagulant market in the future .
-
With frequent personnel changes, domestic pharmaceutical companies have ushered in major adjustments
Time of Update: 2022-05-02
For example, on February 23, Guangshengtang announced that the company recently appointed George Zhang (Zhang Yuhua) as the company's innovative drug holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co.
-
Kangchen Pharmaceutical's KC1036 entered Phase Ib/II clinical study for the treatment of advanced digestive system tumors
Time of Update: 2022-05-02
On February 23, Kangchen Pharmaceutical issued an announcement saying that recently, Kangchen Pharmaceutical's "Phase Ib/II clinical study plan to evaluate the efficacy and safety of KC1036 in the treatment of advanced recurrent or metastatic digestive system tumors" was published in the Chinese Academy of Medical Sciences.
-
What are the changes in the performance of Siemens Healthcare, GE Healthcare and other companies?
Time of Update: 2022-05-02
Siemens Healthineer's revenue of 18 billion euros Siemens Healthineer is mainly composed of four major business segments: imaging, diagnosis, clinical treatment and Varian .
In fiscal 2021, Siemens Healthineers' total revenue increased by 24% year-on-year to 18 billion euros .
-
Fangsheng Pharmaceutical will transfer part of the equity of its holding subsidiary and introduce strategic investors
Time of Update: 2022-05-02
On February 28, Fangsheng Pharmaceutical issued an announcement stating that the third extraordinary meeting of the fifth session of the board of directors of the company in 2022 reviewed and approved the "Proposal on the Transfer of Partial Equity Delivery of the Holding Subsidiary", agreeing that the company and DeVita, Baijun Medical, Kanglai Health, Ruijian Health, and Changsha Baijun signed the Supplementary Agreement (II) to the Convertible Bond Agreement on the issue of loans issued by DeVita Company .
-
Kexing Pharmaceutical's 2021 performance: total revenue of 1.285 billion yuan, a year-on-year increase of 5.31%
Time of Update: 2022-05-02
285 billion yuan in 2021, a year-on-year increase of 5.
31%; net profit attributable to owners of the parent company is 90 million yuan, a year-on-year decrease of 35.
45 yuan, a year-on-year decrease of 51.
83%, a year-on-year decrease of 13.
-
A number of medical companies submit their forms again after the IPO "failed"
Time of Update: 2022-05-02
This means that Inference Medical's first sprint for listing on the Hong Kong Stock Exchange failed .
-
The "Physician Law" has opened the legal floodgate for the implementation of off-label drug use today?
Time of Update: 2022-05-02
The second paragraph of Article 29 of the "Physicians' Law" clearly stipulates that "in special circumstances such as no effective or better treatment methods, after obtaining the patient's explicit informed consent, the physician may use the drug instructions that are not specified but have evidence-based methods.
-
2022 Compressed Air Double-Carbon Energy Saving, Helping Biological Fermentation Industry Summit Forum
Time of Update: 2022-05-02
To this end, the Shanghai Air-standard Compressor Technology Testing Center and the Organizing Committee of the International Bio-Fermentation Exhibition (Jinan) jointly held this summit forum, and invited senior experts from relevant industries to exchange and discuss.
-
Concerned about rare diseases, domestic hemophilia patients urgently need to get rid of the new dilemma of "inaccessible medicine"
Time of Update: 2022-05-02
In this regard, the majority of hemophilia patients through an open letter called on Roche Pharmaceuticals to put patients first and reduce the sales price of Emicizumab injection, in order to better benefit rare disease patients and enter the national medical insurance catalogue as soon as possible.
-
The ophthalmology track is popular, and a batch of domestic new drugs is about to be launched
Time of Update: 2022-05-02
In recent years, a large number of pharmaceutical companies in China have begun to flood into the new ophthalmic drug track .
For example, on February 17, the China Drug Clinical Trial Registration and Information Publicity Platform showed that Zhaoke Ophthalmology Co.
-
Ono Pharma's VelexbruBTK inhibitor approved in Taiwan for the treatment of adult patients with PCNSL
Time of Update: 2022-05-02
Ono Pharmaceutical recently announced that the company's BTK inhibitor Velexbru (tirabrutinib hydrochloride, 80mg tablet) has been approved in Taiwan, China for the treatment of relapsed or refractory B-cell primary central nervous system lymphoma (PCNSL) adult patients .
-
National Medical Insurance Bureau: The scale of direct settlement of general outpatient expenses across provinces continues to increase
Time of Update: 2022-05-02
According to the data, as of the end of January 2022, 53,800 designated medical institutions have been connected to the nationwide direct settlement of hospitalization expenses across provinces .
-
In 2024, the market size of autoimmune drugs may reach nearly 50 billion yuan
Time of Update: 2022-05-02
Incomplete statistics show that as of November 2021, in its R&D pipeline, in addition to the marketed TNF-α inhibitor Yisaipu, there are 5 self-immune drugs under development, 3 of which have completed clinical phase I trials.
-
Vembrolizumab: A 'first in class' ADC to challenge first-line lymphoma treatment
Time of Update: 2022-05-02
At the 2021 American Society of Hematology (ASH) annual meeting, vebotuzumab combined with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) versus R-CHOP (rituximab) The phase III POLARIX study of monoclonal antibody, cyclophosphamide, doxorubicin, vincristine, prednisone) in the first-line treatment of DLBCL has released detailed data and published it simultaneously in the New England Journal of Medicine .
